{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:38:01Z","timestamp":1790519881123,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2515,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"SNUH Research Fund","award":["25-2014-0040"],"award-info":[{"award-number":["25-2014-0040"]}]},{"name":"SNUH Research Fund","award":["03-2015-0430"],"award-info":[{"award-number":["03-2015-0430"]}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HI14C25020000"],"award-info":[{"award-number":["HI14C25020000"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HI12C1544"],"award-info":[{"award-number":["HI12C1544"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s13311-016-0442-6","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T05:25:49Z","timestamp":1464067549000},"page":"824-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":249,"title":["Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Woo-Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsup","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sang","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ick","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ah","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keon-Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Il","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0442-6_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","article-title":"Encephalitis and antibodies to synaptic and neuronal cell surface proteins","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0442-6_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2011-301237","article-title":"Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition","author":"Zuliani","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0442-6_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/cir1038","article-title":"The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project","volume":"54","author":"Gable","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s13311-016-0442-6_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/WCO.0000000000000087","article-title":"Autoimmune encephalitis as differential diagnosis of infectious encephalitis","volume":"27","author":"Armangue","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.0000000000001190","article-title":"The spectrum of acute encephalitis causes, management, and predictors of outcome","volume":"84","author":"Singh","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0442-6_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/jnnp-2012-303807","article-title":"Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens","volume":"84","author":"Hacohen","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0442-6_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0442-6_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2010.026104","article-title":"Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study","volume":"95","author":"Kim","year":"2010","journal-title":"Haematologica"},{"key":"10.1007\/s13311-016-0442-6_bib11","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-016-0442-6_bib12","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-016-0442-6_bib13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","article-title":"IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells","volume":"141","author":"Okada","year":"1988","journal-title":"J Immunol"},{"key":"10.1007\/s13311-016-0442-6_bib14","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: Regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-016-0442-6_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine-40 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1007\/s13311-016-0442-6_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1007\/s13311-016-0442-6_bib17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-016-0442-6_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-016-0442-6_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti\u2013IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0442-6_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term Therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib22","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","article-title":"Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab","volume":"70","author":"Krogias","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaneurol.2015.0579","article-title":"Targeting the interleukin 6 receptor to treat neuromyelitis optica","volume":"72","author":"Irani","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s13311-016-0442-6_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2014.02.011","article-title":"Clinical manifestations and outcomes of the treatment of patients with GABA B encephalitis","volume":"270","author":"Kim","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0442-6_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3988\/jcn.2014.10.2.157","article-title":"Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome","volume":"10","author":"Lim","year":"2014","journal-title":"J Clin Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2015.03.005","article-title":"Clinical manifestations of patients with CASPR2 antibodies","volume":"281","author":"Sunwoo","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-016-0442-6_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/589747","article-title":"The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"47","author":"Tunkel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s13311-016-0442-6_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1007\/s13311-016-0442-6_bib30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE v4.0). Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_403_2010-06-14_QuickReference_5x7.pdf. Accessed April 1, 2015."},{"key":"10.1007\/s13311-016-0442-6_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0442-6_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"key":"10.1007\/s13311-016-0442-6_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/eji.1830200134","article-title":"Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis","volume":"20","author":"Gijbels","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-016-0442-6_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF02740665","article-title":"Physiological and pathological roles of interleukin-6 in the central nervous system","volume":"15","author":"Gruol","year":"1997","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-016-0442-6_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.24200","article-title":"Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms","volume":"76","author":"Irani","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0442-6_bib36","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-016-0442-6_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0442-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0442-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0442-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0442-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:03:33Z","timestamp":1761807813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1878747923014988"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0442-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0442-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0471-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}